Interactions of liposomes with complement leading to adverse reactions

Liposome Technology: Interactions of Liposomes with the Biological Milieu

Volumn , Issue , 2006, Pages 1-23

  Szebeni, Janos ^a   Alving, Carl R ^a   Baranyi, Lajos ^b   Bünger, Rolf ^c  

^a Materiel Command   (United States)

^b Vaccine and Immunology Research Institute   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84979859873     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (64)

1. Haxby JA, Kinsky CB, Kinsky SC. Immune response of a liposomal model membrane. Proc Natl Acad Sci USA 1968; 61:300-307.
2. Kinsky SC, Haxby JA, Zopf DA, Alving CR, Kinsky CB. Complementdependent damage to liposomes prepared from pure lipids and Forssman hapten. Biochemistry 1969; 8:4149-4158.
3. Alving CR, Kinsky SC, Haxby JA, Kinsky CB. Antibody binding and complement fixation by a liposomal model membrane. Biochemistry 1969; 8:1582-1587.
4. Haxby JA, Gotze O, Muller-Eberhard HJ, Kinsky SC. Release of trapped marker from liposomes by the action of purified complement components. Proc Natl Acad Sci USA 1969; 64:290-295.
5. Bradley AJ, Devine DV. The complement system in liposome clearance: can complement deposition be inhibited. Adv Drug Deliv Rev 1998; 1(32):19-29.
6. Szebeni J. The interaction of liposomes with the complement system. Crit Rev Ther Drug Carrier Syst 1998; 15:57-88.
7. Szebeni J. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs and radiocontrast agents. Crit Rev Ther Drug Carr Syst 2001; 18:567-606.
8. Szebeni J. Complement activation-related pseudoallergy: mechanism of anaphylactoid reactions to drug carriers and radiocontrast agents. In: Szebeni J, ed. The Complement System: Novel Roles in Health and Disease. Boston: Kluwer, 2004:399-440.
9. Szebeni J, Baranyi B, Savay S, et al. Liposome-induced pulmonary hypertension:properties and mechanism of a complement-mediated pseudoallergic reaction. Am J Physiol 2000; 279:H1319-H1328.
10. Szebeni J, Fontana JL, Wassef NM, et al. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudo-allergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody. Circulation 1999; 99:2302-2309.
11. Szebeni J, Baranyi B, Savay S, et al. The role of complement activation in hypersensitivity to pegylated liposomal doxorubicin (Doxil1). J Liposome Res 2000; 10:347-361.
12. Szebeni J, Baranyi L, Savay S, et al. The interaction of liposomes with the complement system: in vitro and in vivo assays. Meth Enzymol 2003; 373:136-154.
13. Uziely B, Jeffers S, Isacson R, et al. Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies. J Clin Oncol 1995; 13:1777-1785.
14. Alberts DS, Garcia DJ. Safety aspects of pegylated liposomal doxorubicin in patients with cancer. Drugs 1997; 54(suppl 4):30-45.
15. Dezube BJ. Safety assessment: DoxilR (Doxorubicin HCl liposome injection) in refractory AIDS-related Kaposi’s sarcoma. In: Doxil Clinical Series. Califon, NJ: Gardiner-Caldwell SynerMed, 1996:1-8.
16. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997; 54:15-21.
17. Gabizon AA, Muggia FM. Initial clinical evaluation of pegylated liposomal doxorubicin in solid tumors. In: Woodle MC, Austin SG, eds. Long-Circulating Liposomes: Old Drugs, New Therapeutics. Texas: Landes Bioscience, 1998:155-174.
18. Chanan-Khan A, Szebeni J, Savay S, et al. Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions. Ann Oncol 2003; 14:1430-1437.
19. Levine SJ, Walsh TJ, Martinez A, et al. Cardiopulmonary toxicity after liposomal amphotericin B infusion. Ann Int Med 1991; 114:664-666.
20. Laing RBS, Milne LJR, Leen CLS, Malcolm GP, Steers AJW. Anaphylactic reactions to liposomal amphotericin. Lancet 1994; 344:682.
21. Ringdén O, Andström E, Remberger M, Svahn BM, Tollemar J. Allergic reactions and other rare side effects of liposomal amphotericin. Lancet 1994; 344:1156-1157.
22. de Marie S. Liposomal and lipid-based formulations of amphotericin B. Leukemia 1996; 10(suppl 2):S93-S96.
23. Schneider P, Klein RM, Dietze L, et al. Anaphylactic reaction to liposomal amphotericin (AmBisome). Br J Haematol 1998; 102:1108.
24. Cabriales S, Bresnahan J, Testa D, et al. Extravasation of liposomal daunorubicin in patients with AIDS-associated Kaposi’s sarcoma: a report of four cases [comments]. Oncol Nurs Forum 1998; 25:67-70.
25. Eckardt JR, Campbell E, Burris HA, et al. A phase II trial of DaunoXome, liposome- encapsulated daunorubicin, in patients with metastatic adenocarcinoma of the colon. Am J Clin Oncol 1994; 17:498-501.
26. Fossa SD, Aass N, Paro G. A phase II study of DaunoXome in advanced urothelial transitional cell carcinoma. Eur J Cancer 1998; 34:1131-1132.
27. Gill PS, Espina BM, Muggia F, et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 1995; 13:996-1003.
28. Gill PS, Wernz J, Scadden DT, et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma. J Clin Oncol 1996; 14:2353-2364.
29. Girard PM, Bouchaud O, Goetschel A, et al. Phase II study of liposomal encapsulated daunorubicin in the treatment of AIDS-associated mucocutaneous Kaposi’s sarcoma. AIDS 1996; 10:753-757.
30. Guaglianone P, Chan K, DelaFlor-Weiss E, et al. Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome). Invest New Drugs 1994; 12:103-110.
31. Money-Kyrle JF, Bates F, Ready J, et al. Liposomal daunorubicin in advanced Kaposi’s sarcoma: a phase II study. Clin Oncol (R Coll Radiol) 1993; 5:367-371.
32. Richardson DS, Kelsey SM, Johnson SA, et al. Early evaluation of liposomal daunorubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphoma. Invest New Drugs 1997; 15:247-253.
33. Sculier JP, Coune A, Brassinne C, et al. Intravenous infusion of high doses of liposomes containing NSC 251635, a water-insoluble cytostatic agent. A pilot study with pharmacokinetic data. J Clin Oncol 1986; 4:789-797.
34. Masaki T, Okada N, Yasuda R, Okada H. Assay of complement activity in human serum using large unilamellar liposomes. J Immunol Meth 1989; 123:19-24.
35. Mold C, Gewurz H. Activation of human complement by liposomes: serum factor requirement for alternative pathway activation. J Immunol 1980; 125:696-700.
36. Okada N, Yasuda T, Tsumita T, Okada H. Membrane sialoglycolipids regulate the activation of alternative complement pathway by liposomes containing trinitrophenylaminocaproyldipalmitoylphosphatidylethaolamine. Immunology 1983; 48:129-140.
37. Ozato K, Ziegler HK, Henney CS. Liposomes as model membrane systems for immune attack. II. The interaction of complement and K cell populations with immobilized liposomes. J Immunol 1978; 121:1383-1388.
38. Richards RL, HabbersettRC, Scher I, et al. Influence of vesicle size on complementdependent immune damage to liposomes. Biochim Biophys Acta 1986; 855:223-230.
39. Roerdink F, Wassef NM, Richardson EC, Alving CR. Effects of negatively charged lipids on phagocytosis of liposomes opsonized by complement. Biochim Biophys Acta 1983; 734:33-39.
40. Alving CR, Urban KA, Richards RL. Influence of temperature on complementdependent immune damage to liposomes. Biochim Biophys Acta 1980; 600:117.
41. Harashima H, Sakata K, Funato K, Kiwada H. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm Res 1994; 11:402-406.
42. Liu D, Liu F, Song YK. Recognition and clearance of liposomes containing phosphatidylserine are mediated by serum opsonin. Biochim Biophys Acta 1995; 1235:140-146.
43. Bonte F, Juliano RL. Interactions of liposomes with serum proteins. Chem Phys Lipids 1986; 40:359-372.
44. Chonn A, Cullis PR, Devine DV. The role of surface charge in the activation of the classical and alternative pathways of complement by liposomes. J Immunol 1991; 146:4234-4241.
45. Cunningham CM, Kingzette M, Richards RL, et al. Activation of human complement by liposomes: a model for membrane activation of the alternative pathway. J Immunol 1979; 122:1237-1242.
46. Funato K, Yoda R, Kiwada H. Contribution of complement system on destabilization of liposomes composed of hydrogenated egg phosphatidylcholine in rat fresh plasma. Biochim Biophys Acta 1992; 1103:198-204.
47. Harashima H, Sakata K, Funato K, Kiwada H. Enhanced hepatic uptake of liposomes through complement activation depending on the size of liposomes. Pharm Res 1994; 11:402.
48. Mayer MM. Complement and complement fixation. In: Kabat EA, Mayer MM, eds. Kabat Mayer’s Experimental Immunochemistry. 2nd ed. Springfield, IL:Charles C. Thomas, 1961:133-240.
49. Plank C, Tang MX, Wolfe AR, Szoka FCJ. Branched cationic peptides for gene delivery: role of type and number of cationic residues in formation and in vitro activity of DNA polyplexes. Hum Gene Ther 1999; 10:319-332.
50. Fontana JL, Welborn L, Mongan PD, et al. Oxygen consumption and cardiovascular function in children during profound intraoperative normovolemic hemodilution. Anesth Analg 1995; 80:219-225.
51. Szebeni J, Wassef NM, Spielberg H, Rudolph AS, Alving CR. Complement activation in rats by liposomes and liposome-encapsulated hemoglobin: evidence for anti-lipid antibodies and alternative pathway activation. Biochem Biophys Res Comm 1994; 205:255-263.
52. Szebeni J, Wassef NM, Rudolph AS, Alving CR. Complement activation in human serum by liposome-encapsulated hemoglobin: the role of natural antiphospholipid antibodies. Biochim Biophys Acta 1996; 1285:127-130.
53. Szebeni J, Wassef NM, Hartman KR, Rudolph AS, Alving CR. Complement activation in vitro by the red blood cell substitute, liposome-encapsulated hemoglobin:mechanism of activation and inhibition by soluble complement receptor type 1. Transfusion 1997; 37:150-159.
54. Szebeni J, Spielberg H, Cliff RO, et al. Complement activation and thromboxane A2 secretion in rats following administration of liposome-encapsulated hemoglobin:inhibition by soluble complement receptor type 1. Art Cells Blood Subs and Immob Biotechnol 1997; 25:379-392.
55. Szebeni J, Baranyi L, Savay S, et al. Role of complement activation in hypersensitivity reactions to Doxil and HYNIC-PEG liposomes: experimental and clinical studies. J Liposome Res 2002; 12:165-172.
56. Aguado JM, Hidalgo M, Moya I, et al. Ventricular arrhythmias with conventional and liposomal amphotericin. Lancet 1993; 342(8881):1239.
57. Coune A, Sculier JP, Frühling J, et al. IV administration of a water-insoluble antimitotic compound entrapped in liposomes. Preliminary report on infusion of large volumes of liposomes to man. Cancer Treat Rep 1983; 67:1031-1033.
58. Skubitz KM, Skubitz AP. Mechanism of transient dyspnea induced by pegylated- liposomal doxorubicin (Doxil). Anticancer Drugs 1998; 9:45-50.
59. Cheung AK, Parker CJ, Hohnholt M. Soluble complement receptor type 1 inhibits complement activation induced by hemodialysis membranes in vitro. Kidney Int 1994; 46:1680-1687.
60. Skroeder NR, Jacobson SH, Lins LE, Kjellstrand CM. Acute symptoms during and between hemodialysis: the relative role of speed, duration, and biocompatibility of dialysis. Artif Organs 1994; 18:880-887.
61. Skroeder NR, Kjellstrand P, Holmquist B, Kjellstrand CM, Jacobson SH. Individual differences in biocompatibility responses to hemodialysis. Int J Artif Organs 1994; 17:521-530.
62. Brouwers AH, De Jong DJ, Dams ET, et al. Tc-99m-PEG-Liposomes for the evaluation of colitis in Crohn’s disease. J Drug Target 2000; 8:225-233.
63. 99mTc-PEG liposomes for the scintigraphic detection of infection and inflammation: clinical evaluation. J Nucl Med 2000; 41:622.
64. Small P, Satin R, Palayew MJ, Hyams B. Prophylactic antihistamines in the management of radiographic contrast reactions. Clin Allergy 1982; 12:289-294.